focus -WSS

focus

author：explore 2025-09-27 23:12:00 - browse：8

An advisory committee to the Food and Drug Administration will convene on Tuesday to evaluate the benefits of renal denervation, a one-time surgical procedure that works to reduce blood pressure. The promise — and the potential market — is enormous, but the data on how well the procedure works remains contentious.

The committee will evaluate data from two companies vying for market approval: ReCor Medical, a startup owned by Japanese company Otsuka Medical Devices, and device giant Medtronic, both of which have made surgical systems to treat hypertension.

Data from an analysis of three randomized clinical trials of ReCor Medical’s device showed a modest decrease in blood pressure after two months compared to a control group that received a placebo procedure. Medtronic’s late-stage trial showed that renal denervation reduced hypertension when measuring blood pressure in the doctor’s office, but did not show a reduction in blood pressure when patients measured it at home over 24 hours. At-home blood pressure is considered the more accurate measure, as blood pressure levels tend to artificially rise with anxiety in the clinic. Neither study presented serious safety concerns.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Private equity deals in Medicare Advantage declines

WSS

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Gain of function research would be limited under House proposal

Surge of respiratory disease in China has likely explanation

A daunting task: navigating dual Medicare, Medicaid eligibility

Weight loss drug costs may need more research, senator suggests

To avoid data mishandling cases, universities eye AI and other tools

focus

focus

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

The dental labor crisis is a moment of opportunity

Bright Health sells Medicare Advantage business to Molina

FDA's Woodcock to retire early next year

As demand for Covid shots wanes, Moderna seeks its next success

Readout LOUD podcast: How biotech is using artificial intelligence

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout LOUD podcast: How biotech is using artificial intelligence

Bright Health sells Medicare Advantage business to Molina

The dental labor crisis is a moment of opportunity

leisure time

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Wegovy, Zepbound and weight loss drugs that preserve muscle

Weight loss drug costs may need more research, senator suggests

BioAge raises $170M for combination therapy with Zepbound

Anthos stroke drug appears safer than common blood thinner

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Wikipedia

hotspot

hotspot

Wikipedia